Photocure ASA (OSL:PHO)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.86B |
| Revenue (ttm) | 532.58M |
| Net Income (ttm) | -1.52M |
| Shares Out | 26.61M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | 35.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,047 |
| Average Volume | 123,953 |
| Open | 69.50 |
| Previous Close | 69.80 |
| Day's Range | 67.30 - 69.50 |
| 52-Week Range | 48.50 - 79.80 |
| Beta | 0.34 |
| RSI | 50.98 |
| Earnings Date | Apr 13, 2026 |
About Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]
Full Company ProfileFinancial Performance
In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.52% less than in 2024.
Financial StatementsNews
Photocure ASA: Update on Regulatory Classification for OAY Equipment
OSLO, Norway, April 13, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed o...
Photocure ASA Earnings Call Transcript: Q4 2025
Q4 and FY25 saw record product revenue, double-digit growth in North America, and 11 straight quarters of positive EBITDA. Strategic partnerships, innovation in AI diagnostics, and strong cash position support continued operating leverage and growth, with U.S. market under-penetrated.
Photocure ASA: Results for the fourth quarter of 2025
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a...
Photocure ASA Earnings Call Transcript: Q3 2025
Q3 saw 12% revenue growth and positive EBITDA for the 10th straight quarter, driven by strong U.S. and European performance, new installations, and AI partnerships. Guidance narrowed to 8%-10% growth, with continued focus on U.S. expansion and innovation.
Photocure ASA: Results for the third quarter of 2025
OSLO, Norway , Oct. 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an...
Photocure ASA Earnings Call Transcript: Q2 2025
Revenue grew 11% year-over-year to a record NOK 135.6 million, with strong gains in both North America and Europe, and positive EBITDA for the ninth consecutive quarter. ForTec mobile solutions now exceed 10% of business, and strategic expansion into Spain and new product development are expected to drive future growth.
Photocure ASA: Results for the second quarter of 2025
OSLO, Norway , July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and ...
Photocure ASA Earnings Call Transcript: Q1 2025
Q1 2025 saw 7% revenue growth and positive EBITDA, driven by strong European performance and expanding mobile solutions in the U.S. Despite a sharp decline in FLEX sales, rigid kit growth and new account activations offset the impact. Guidance for 7%-11% revenue growth in 2025 is reaffirmed.
Photocure ASA: Results for the first quarter of 2025
OSLO, Norway , May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an ...
Photocure ASA Earnings Call Transcript: Q4 2024
Q4 delivered 13% revenue growth and positive EBITDA, with strong US and European performance, expanding partnerships, and a robust cash position. Outlook for 2025 is 7–11% product revenue growth and further EBITDA improvement, driven by new launches and regulatory milestones.
Photocure ASA: Results for the fourth quarter of 2024
OSLO, Norway , Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA...
Photocure ASA Earnings Call Transcript: Q3 2024
Q3 delivered 12% revenue growth and positive EBITDA, with strong performance in both U.S. and Europe. Mobile solutions and equipment upgrades are driving expansion, while regulatory milestones in China and the EU are expected to yield significant future cash inflows.
Photocure ASA: Results for the third quarter of 2024
OSLO, Norway , Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBIT...
Photocure ASA Earnings Call Transcript: Q2 2024
Q2 2024 saw 6% product revenue growth, positive EBITDA, and a strengthened cash position. U.S. and European markets showed strong momentum, with raised guidance for Saphira tower placements and key partnerships advancing access and innovation.
Photocure ASA: Results for the second quarter of 2024
OSLO, Norway , Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix ® /Cysview ® revenues of NOK 122.4 million in the second quarter of 2024 (Q2 20...